Compare IMMR & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | ARMP |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.4M | 199.7M |
| IPO Year | 1999 | 1996 |
| Metric | IMMR | ARMP |
|---|---|---|
| Price | $6.55 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | ★ 336.3K | 75.7K |
| Earning Date | 09-14-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $2.40 |
| 52 Week High | $8.05 | $14.98 |
| Indicator | IMMR | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 46.59 |
| Support Level | $6.29 | $2.77 |
| Resistance Level | $6.83 | $3.96 |
| Average True Range (ATR) | 0.20 | 0.44 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 6.58 | 43.35 |
Immersion Corp is a licensing company focused on the acceleration, and scaling, through licensing, of haptic technologies that allow people to use sense of touch to engage with products and experience the digital world around them. Its patents cover a wide range of digital technologies and ways in which touch-related technology can be incorporated into and between hardware products and components, systems software, application software, and digital content. It operates in two operating segments: Immersion and Barnes & Noble Education. The majority of revenue is derived from Barnes & Noble Education segment which is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.